Can Actelion Founder Clozel Recreate Another Top Biotech Post-J&J Sale?
Executive Summary
Actelion's M&A deal with J&J vindicates the strategy of cardiologist Jean-Paul Clozel, who co-founded the Swiss firm with his wife Martine and friends in 1997, and positions him for another shot at biotech success.
You may also be interested in...
Canny Clozel Gets Another $230m From J&J For Idorsia Hypertension Drug
Idorsia, the Swiss company spun out of Actelion after the latter was bought by J&J, is to get another windfall from the US major which has triggered an option to co-develop the Phase III-ready drug aprocitentan.
Deal Watch: Best Value For Smaller Firms Lies In The Back-End
With more deals on earlier-stage platform technologies and compounds, the companies offering such assets need to take a rational approach to pricing – accepting a lot of potential back-end compensation – to get fair value, one analyst says.
J&J's Actelion Courtship Seen Unaffected By Macitentan MAESTRO Failure
Johnson & Johnson is expected to keep pursuing Actelion despite news the target's pulmonary arterial hypertension drug macitentan missed a primary endpoint in a Phase III study of patients with PAH due to Eisenmenger Syndrome.